Robin McKenzie

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial
    Sarah A Frech
    IOMAI Corporation, Gaithersburg, MD, USA
    Lancet 371:2019-25. 2008
  2. ncbi Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial
    R McKenzie
    Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N Broadway, HH, Rm 203, Baltimore, MD 21205, USA
    Vaccine 24:3735-45. 2006
  3. ncbi A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, United States
    Vaccine 26:4731-9. 2008
  4. ncbi Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate
    Robin McKenzie
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Vaccine 26:3291-6. 2008
  5. ncbi Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, United States
    Vaccine 25:3684-91. 2007
  6. ncbi Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults
    Robin McKenzie
    Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N Broadway, HH, Rm 203, Baltimore, MD 21205, USA
    Infect Immun 74:994-1000. 2006
  7. ncbi Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens
    Andrea J Feller
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 29:8487-9. 2011
  8. ncbi Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
    David N Taylor
    Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1179-81. 2008
  9. ncbi Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
    David N Taylor
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 42:1283-8. 2006
  10. ncbi Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19
    Robin McKenzie
    Department of Medicine, Johns Hopkins University, Johns Hopkins Bayview Medical Center, MD, USA
    J Infect Dis 204:60-4. 2011

Collaborators

Detail Information

Publications15

  1. ncbi Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial
    Sarah A Frech
    IOMAI Corporation, Gaithersburg, MD, USA
    Lancet 371:2019-25. 2008
    ..We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to the skin by patch in travellers to Mexico and Guatemala...
  2. ncbi Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial
    R McKenzie
    Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N Broadway, HH, Rm 203, Baltimore, MD 21205, USA
    Vaccine 24:3735-45. 2006
    ..We conclude that SsWC was immunogenic and protective in animal studies and well tolerated and immunogenic in a Phase I trial...
  3. ncbi A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, United States
    Vaccine 26:4731-9. 2008
    ..Higher serum anti-CS3 IgA titers at the time of challenge correlated with less severe diarrheal illness...
  4. ncbi Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate
    Robin McKenzie
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Vaccine 26:3291-6. 2008
    ..Days of fecal shedding of the vaccine strain, but not dose ingested, correlated with stronger immune responses. These results suggest that to be effective an attenuated Shigella vaccine must colonize well...
  5. ncbi Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study
    Robin McKenzie
    Division of Infectious Diseases, Johns Hopkins University, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, United States
    Vaccine 25:3684-91. 2007
    ..An enterotoxigenic Escherichia coli (ETEC) vaccine could reduce diarrhea among children in developing countries and travelers to these countries. The heat-labile toxin (LT) of ETEC is immunogenic but too toxic for oral or nasal vaccines...
  6. ncbi Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults
    Robin McKenzie
    Center for Immunization Research, Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 624 N Broadway, HH, Rm 203, Baltimore, MD 21205, USA
    Infect Immun 74:994-1000. 2006
    ..Based on its superior immunogenicity, which was comparable to that of a virulent ETEC strain and other ETEC vaccine candidates, PTL-003 will be developed further as a component of a live, oral attenuated ETEC vaccine...
  7. ncbi Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens
    Andrea J Feller
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 29:8487-9. 2011
    ..Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen...
  8. ncbi Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
    David N Taylor
    Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1179-81. 2008
    ..Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers...
  9. ncbi Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
    David N Taylor
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 42:1283-8. 2006
    ..This double-blind, placebo-controlled study was conducted to assess the efficacy of the nonabsorbed oral antibiotic rifaximin to prevent shigellosis in volunteers challenged with Shigella flexneri...
  10. ncbi Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19
    Robin McKenzie
    Department of Medicine, Johns Hopkins University, Johns Hopkins Bayview Medical Center, MD, USA
    J Infect Dis 204:60-4. 2011
    ..These studies establish the relative pathogenicity of ETEC expressing newer class 5 fimbriae and suggest suitability of the LT|CS17-ETEC challenge model for interventional trials...
  11. ncbi Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial
    Charles Flexner
    Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 50:1041-52. 2010
    ..Clinical trial registration. ClinicalTrials.gov registration number: NCT00036452...
  12. ncbi Lactoferrin for the prevention of post-antibiotic diarrhoea
    Alison M Laffan
    Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21224, USA
    J Health Popul Nutr 29:547-51. 2011
    ..Fewer patients in the lactoferrin group experienced diarrhoea compared to controls (p = 0.023). Based on the findings, it is concluded that human lactoferrin may reduce post-antibiotic diarrhoea...
  13. ncbi Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers
    B D Kirkpatrick
    University of Vermont College of Medicine, Department of Medicine, Unit of Infectious Diseases, 95 Carrigan Drive, 110 Stafford Building, Burlington, VT 05405, USA
    Vaccine 24:116-23. 2006
    ..The SPI-2 mutant vaccine, M01ZH09, is a promising typhoid vaccine candidate and deserves further study as a vectoring system for heterologous vaccine antigens...
  14. ncbi Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum
    Gregory M Glenn
    IOMAI Corporation, 20 Firstfield Road, Gaithersburg, MD 20878, USA
    Infect Immun 75:2163-70. 2007
    ....
  15. ncbi Gastrointestinal infection among international travelers globally
    Zoe Greenwood
    Victorian Infectious Diseases Service, Royal Melbourne Hospital, Victoria, Australia
    J Travel Med 15:221-8. 2008
    ..The objective of this study was to analyze infections associated with oral ingestion of pathogens in international travelers in relation to place of exposure...